Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glenmark Ups Respiratory Play But Is The Digihaler Disruptive?

Executive Summary

Glenmark Pharmaceuticals Ltd., which is building its global respiratory play, appears to be betting big on its new next-generation digital inhaler that the India firm underscores is meaningful innovation that patients can afford. The jury, though, appears to be still out on whether India’s first digital dose inhaler (DDI) can help move the adherence needle.

You may also be interested in...



Glenmark’s Digital Asthma Inhaler: Is It Really A Roaring Success?

Just months into its launch, over 100,000 patients in India are said to be using Glenmark’s “Digihaler” for asthma and chronic obstructive pulmonary disorder (COPD) medication. But some key opinion leaders appear unconvinced of the disruptive potential of the firm’s next generation digital dose inhaler.

Mylan's Generic Advair FDA Filing Puts Added Squeeze On GSK

The increasing urgency for GlaxoSmithKline PLC to build up its overall respiratory portfolio was underscored when Mylan NV confirmed it has submitted an abbreviated new drug application (ANDA) to the FDA for launch of the first generic alternative to GSK's top-selling Seretide Evohaler (salmeterol xinafoate + fluticasone propionate), known in the US as Advair Diskus.

Seretide Competition Builds Up But Substitutability Holds Key?

More possible competition is building for GlaxoSmithKline's blockbuster salmeterol and fluticasone combination, with a second Indian firm teaming up with the Polish biopharmaceutical company Celon to produce a version of the product.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC065311

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel